Tandem Mobi® mobile app

Tandem Mobi System

Only for iPhone

Free

iPhone

Tandem Mobi is the world’s smallest, durable automated insulin delivery system.1 Impressively small and offering next-level convenience and discretion, Tandem Mobi is controllable with a compatible, personal iPhone.* Use of the Tandem Mobi mobile app requires a prescription. Always consult a healthcare professional for information about how to manage diabetes. Features * Mobile Control: The Tandem Mobi system is controllable from a compatible, personal iPhone, offering discreet and convenient access to therapy data and pump functions* * Advanced Therapy Visualization: View a 24-hour graphical representation of glucose readings (CGM and BGM), basal and bolus events, insulin on board, carbohydrate intake, suspensions, and other therapy-related data * Pump Status Monitoring: Real-time visibility into pump battery level, available insulin, active Personal Profile, CGM sensor and transmitter status, and more * Customizable User Experience: Personal Profiles and activity settings allow users to tailor therapy to their lifestyle, with enhanced personalization features * AutoBolus: The only system with AutoBolus to help with missed meal boluses and preventing hyperglycemia† * Seamless Data Sync: Wireless data uploads to the Tandem Source platform to ensure therapy data is securely backed up and accessible‡ ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. The electronic instructions for use for the Tandem Mobi mobile app (Basic UDI-DI: 00389152690940) can be accessed through the Tandem Mobi user guide, available here: https://www.tandemdiabetes.com/support/resources/documents. Upon request, a printed copy of the user guide can be provided within seven days at no additional cost. If the language set on your smartphone is supported by the mobile app, then the mobile app will display in that language. If the language set on your smartphone is not supported by the mobile app, then the mobile app will display in English. *The mobile app requires a compatible smartphone model and operating system (sold separately). †If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ+ technology calculates an AutoBolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. ‡Uploads to the Tandem Source platform do not take place in real time and should not be relied upon by healthcare providers, pump users, or caregivers for remote patient monitoring. Standard carrier data rates may apply. Smartphone sold separately. Reference 1. As of Dec., 2025. Data on file, Tandem Diabetes Care.

  • 3.3
    out of 5
    250 Ratings

• Introducing multi-language support • Overall app performance updates • Supports the Dexcom 15-day G7 sensor with dynamic warmup display. Note, this requires users to update their Tandem Mobi pump software to 7.9.1.

The developer, Tandem Diabetes Care Inc., indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .

  • Data Not Linked to You

    The following data may be collected but it is not linked to your identity:

    • Usage Data
    • Diagnostics

Privacy practices may vary, for example, based on the features you use or your age. Learn More

The developer has not yet indicated which accessibility features this app supports. Learn More

Seller
Tandem Diabetes Care, Inc.
Size
160.7 MB
Category
Medical
Compatibility
Requires iOS 18.0 or later.
  • iPhone
    Requires iOS 18.0 or later.
Languages
English
Age Rating
4+
Medical Device
Yes
  • Tandem Diabetes Care Inc. indicated this app is a regulated medical device and complies with United States law.
  • The information below has not been verified by Apple.
  • FDA Owner/Operator Number
  • 10039506
  • Address
  • 12400 High Bluff DR
    San Diego California 92130
    United States
  • Phone Number
  • +1 858-366-6900
  • Email
  • tandemcares@tandemdiabetes.com
  • Use Statement
  • The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices.

    The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 2 years of age and greater.

    Control-IQ+ technology is intended for use with compatible interoperable continuous glucose monitors (iCGM), alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.

    Control-IQ+ technology is not a substitute for your own active diabetes management. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus inpersons 18 years of age and greater. Control-IQ+ technology is intended for single patient use and requires a prescription
  • Safety Information
  • For important safety information, refer to https://www.tandemdiabetes.com/legal/important-safety-information/tandem-mobi-control-iq-plus
  • Instructions for Use
  • Visit the developer site
Copyright
© 2026 Tandem Diabetes Care, Inc. All rights reserved.